Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth

Lefesvre, Pierre; Attema, Joline; Bekkum, Dirk van

doi:10.1186/1471-2407-2-17

Cited by 8 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Independently of the vector system selected, the tumor response ranges from sufficient [8,9,10,11,12,13,14,16] to no response [25]. A previously published study reported a heterogeneous tumor response of different breast-cancer cell lines within the same tumor model [17], suggesting tumor cell-dependent differences in susceptibility to endostatin treatment.…”

Section: Discussionmentioning

confidence: 97%

Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model

Kurdow¹,

Boehle²,

Ruhnke³

et al. 2003

Langenbeck's Archives of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model

Kurdow¹,

Boehle²,

Ruhnke³

et al. 2003

Langenbeck's Archives of Surgery

View full text Add to dashboard Cite

show abstract

Tumor stroma-associated antigens for anti-cancer immunotherapy

Hofmeister

Vetter

Schrama

et al. 2005

Cancer Immunol Immunother

View full text Add to dashboard Cite

Immunotherapy has been widely investigated for its potential use in cancer therapy and it becomes more and more apparent that the selection of target antigens is essential for its efficacy. Indeed, limited clinical efficacy is partly due to immune evasion mechanisms of neoplastic cells, e.g. downregulation of expression or presentation of the respective antigens. Consequently, antigens contributing to tumor cell survival seem to be more suitable therapeutic targets. However, even such antigens may be subject to immune evasion due to impaired processing and cell surface expression. Since development and progression of tumors is not only dependent on cancer cells themselves but also on the active contribution of the stromal cells, e.g. by secreting growth supporting factors, enzymes degrading the extracellular matrix or angiogenic factors, the tumor stroma may also serve as a target for immune intervention. To this end several antigens have been identified which are induced or upregulated on the tumor stroma. Tumor stroma-associated antigens are characterized by an otherwise restricted expression pattern, particularly with respect to differentiated tissues, and they have been successfully targeted by passive and active immunotherapy in preclinical models. Moreover, some of these strategies have already been translated into clinical trials.

show abstract

Anti-cancer therapies targeting the tumor stroma

Hofmeister

Schrama

Becker

2007

Cancer Immunol Immunother

149

View full text Add to dashboard Cite

For anti-tumor therapy different strategies have been employed, e.g., radiotherapy, chemotherapy, or immunotherapy. Notably, these approaches do not only address the tumor cells themselves, but also the tumor stroma cells, e.g., endothelial cells, fibroblasts, and macrophages. This is of advantage, since these cells actively contribute to the proliferative and invasive behavior of the tumor cells via secretion of growth factors, angiogenic factors, cytokines, and proteolytic enzymes. In addition, tumor stroma cells take part in immune evasion mechanisms of cancer. Thus, approaches targeting the tumor stroma attract increasing attention as anti-cancer therapy. Several molecules including growth factors (e.g., VEGF, CTGF), growth factor receptors (CD105, VEGFRs), adhesion molecules (alphavbeta3 integrin), and enzymes (CAIX, FAPalpha, MMPs, PSMA, uPA) are induced or upregulated in the tumor microenvironment which are otherwise characterized by a restricted expression pattern in differentiated tissues. Consequently, these molecules can be targeted by inhibitors as well as by active and passive immunotherapy to treat cancer. Here we discuss the results of these approaches tested in preclinical models and clinical trials.

show abstract

Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth

Cited by 8 publications

References 34 publications

Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model

Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model

Tumor stroma-associated antigens for anti-cancer immunotherapy

Anti-cancer therapies targeting the tumor stroma

Contact Info

Product

Resources

About